INMACULADA
PÉREZ CAMACHO
PERSONAL INVESTIGADOR GARANTIA JUVENIL
Publikationen (40) Publikationen von INMACULADA PÉREZ CAMACHO
2024
-
Long or complicated mpox in patients with uncontrolled HIV infection
Journal of Medical Virology, Vol. 96, Núm. 3
-
Whole-genome characterisation of Escherichia coli isolates from patients with bacteraemia presenting with sepsis or septic shock in Spain: a multicentre cross-sectional study
The Lancet Microbe, Vol. 5, Núm. 4, pp. e390-e399
2023
-
Conventional Hospitalization versus Sequential Outpatient Parenteral Antibiotic Therapy for Staphylococcus aureus Bacteremia: Post-Hoc Analysis of a Multicenter Observational Cohort
Antibiotics, Vol. 12, Núm. 1
-
Role of IP-10 to Predict Clinical Progression and Response to IL-6 Blockade With Sarilumab in Early COVID-19 Pneumonia. A Subanalysis of the SARICOR Clinical Trial
Open Forum Infectious Diseases, Vol. 10, Núm. 4
2022
-
Early Use of Sarilumab in Patients Hospitalized with COVID-19 Pneumonia and Features of Systemic Inflammation: The SARICOR Randomized Clinical Trial
Antimicrobial Agents and Chemotherapy, Vol. 66, Núm. 2
-
Impact of ceftazidime/avibactam versus best available therapy on mortality from infections caused by carbapenemase-producing Enterobacterales (CAVICOR study)
The Journal of antimicrobial chemotherapy, Vol. 77, Núm. 5, pp. 1452-1460
2021
-
Epidemiologic changes in bloodstream infections in Andalucía (Spain) during the last decade
Clinical Microbiology and Infection, Vol. 27, Núm. 2, pp. 283.e9-283.e16
-
Revisiting the epidemiology of bloodstream infections and healthcare-associated episodes: results from a multicentre prospective cohort in Spain (PRO-BAC Study)
International Journal of Antimicrobial Agents, Vol. 58, Núm. 1
2020
2019
2017
-
KIR2DS2 as predictor of thrombocytopenia secondary to pegylated interferon-alpha therapy
Pharmacogenomics Journal, Vol. 17, Núm. 4, pp. 360-365
-
Week 4 response predicts sustained virological response to all-oral direct-acting antiviral-based therapy in cirrhotic patients with hepatitis C virus genotype 3 infection
Clinical Microbiology and Infection, Vol. 23, Núm. 6, pp. 409.e5-409.e8
2016
-
Efficacy and safety of switching to abacavir/lamivudine (ABC/3TC) plus rilpivirine (RPV) in virologically suppressed HIV-infected patients on HAART
European Journal of Clinical Microbiology and Infectious Diseases, Vol. 35, Núm. 5, pp. 815-819
-
Hepatic safety of rilpivirine/emtricitabine/tenofovir disoproxil fumarate fixed-dose single-tablet regimen in HIV-infected patients with active hepatitis C virus infection: The hepatic study
PLoS ONE, Vol. 11, Núm. 5
-
Liver toxicity of current antiretroviral regimens in HIV-infected patients with chronic viral hepatitis in a real-life setting: The HEPAVIR SEG-HEP Cohort
PLoS ONE, Vol. 11, Núm. 2
2015
-
Evaluation of eosinophilia in immigrants in Southern Spain using tailored screening and treatment protocols: A prospective study
Travel Medicine and Infectious Disease, Vol. 13, Núm. 4, pp. 315-321
2013
-
Adipose mesenchymal stromal cells isolated from type 2 diabetic patients display reduced fibrinolytic activity
Diabetes, Vol. 62, Núm. 12, pp. 4266-4269
-
Baseline risk factors for relapse in HIV/HCV co-infected patients treated with PEG-IFN/RBV
Infection, Vol. 41, Núm. 1, pp. 21-26
-
Incidence of Liver Damage of Uncertain Origin in HIV Patients Not Co-Infected with HCV/HBV
PLoS ONE, Vol. 8, Núm. 7
-
Recomendaciones de GESIDA/Secretaría del Plan Nacional sobre el Sida para el tratamiento de la tuberculosis en adultos infectados por el virus de la inmunodeficiencia humana (actualización enero de 2013)
Enfermedades Infecciosas y Microbiologia Clinica, Vol. 31, Núm. 10, pp. 672-684